Skip to content

Regulatory mechanism and clinical significance of LncRNA02583 in vascular endothelial injury in patients with type 2 diabetes

Regulatory mechanism and clinical significance of LncRNA02583 in vascular endothelial injury in patients with type 2 diabetes

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030362
Enrollment
Unknown
Registered
2020-02-29
Start date
2020-02-27
Completion date
Unknown
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Healthy control group:N/A
T2DM patients group:N/A

Sponsors

Zhuhai People's Hospital (Zhuhai hospital affiliated to Ji'nan University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 79 Years

Inclusion criteria

Inclusion criteria: T2DM patients: 1. Aged >= 30 years when first diagnosed with T2DM, and aged >= 55 years at registration; 2. Accompanied by a major cardiovascular history (stroke, myocardial infarction, hospitalization with transient ischemia, unstable angina pectoris, coronary heart disease, peripheral vascular regeneration, secondary vascular disease with amputation) or at least one other cardiovascular disease risk Factors such as a large amount of proteinuria (urine protein creatinine ratio> 300 µg / mg), proliferative retinopathy, retinal photocoagulation therapy, macular edema, blindness caused by diabetes), smoking, total cholesterol> 6.0 mml / L, HDL 30-300 µg / mg) and duration of diabetes >=10 years; 3. Registered patients >= 65 years old. Healthy patients: 1. Any gender, aged 30-79 years; 2. With normal blood glucose, blood pressure, blood lipids, and BMI greater than 18.0 and less than 24.0 can be included.

Exclusion criteria

Exclusion criteria: T2DM patients: 1. Certain contraindications to ACEI inhibitor therapy; 2. Except for the use of perindopril 2mg / day or 4mg / day, a definitive indication for ACE inhibitors; 3. With definite indication or contraindication for thiazide diuretics; 4. With affirmative contraindications or indications of glizide; 5. Positive indications or positive contraindications to reduce HbA1c to 6.5% or below; 6. Patients who currently need long-term treatment with full dose or bedtime insulin; 7. Patients have been participating in other research projects (current or up to last month); 8. Other reasons that do not meet the criteria for participation in the study. Healthy patients: 1. With history of hypertension, hyperlipidemia; 2. With history of diabetes, cardiovascular disease, other diseases such as liver disease, peptic ulcer, tumor, etc..

Design outcomes

Primary

MeasureTime frame
Related gene expression;

Countries

China

Contacts

Public ContactYang Yang

Zhuhai People's Hospital (Zhuhai Hospital affiliated to J'nan University)

362625416@qq.com+86 15975636452

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026